DAMORA THERAPEUTICS, INC. Accumulated Other Comprehensive Income
DAMORA THERAPEUTICS, INC. (DMRA) had Accumulated Other Comprehensive Income of $732.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-10
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $732.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $754.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $802.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $823.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $732.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $754.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $802.00K 10-Q · filed 2026-08-10 |
| 2025-09-30 | $823.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $809.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $300.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $97.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $665.00K 10-Q · filed 2024-11-01 |
| 2024-06-30 | $197.00K 8-K · filed 2024-10-07 |
| 2024-03-31 | $326.00K 10-Q · filed 2024-04-29 |
| 2023-12-31 | $380.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $46.00K 10-Q · filed 2023-11-06 |
| 2023-06-30 | -$137.00K 10-Q · filed 2023-07-31 |
| 2023-03-31 | -$127.00K 10-Q · filed 2023-04-28 |
| 2022-12-31 | -$244.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | -$1.93M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$1.50M 10-Q · filed 2022-07-29 |
| 2022-03-31 | -$695.00K 10-Q · filed 2022-04-29 |
| 2021-12-31 | -$320.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | -$89.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $246.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $70.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $674.00K 10-K · filed 2022-02-17 |
| 2020-09-30 | -$315.00K 10-Q · filed 2020-12-11 |
| 2019-12-31 | -$2.45M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |